Fulcrum Therapeutics Inc FULC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FULC is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $7.13
- Day Range
- $7.05–7.22
- 52-Week Range
- $2.43–13.70
- Bid/Ask
- $7.12 / $7.14
- Market Cap
- $443.78 Mil
- Volume/Avg
- 261,291 / 645,810
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 155.84
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 89
- Website
- https://www.fulcrumtx.com
Comparables
Valuation
|
Metric
|
FULC
|
CBAY
|
GBIO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.88 | 12.65 | 0.95 |
Price/Sales | 155.84 | 111.01 | 31.67 |
Price/Cash Flow | — | — | — |
Price/Earnings
FULC
CBAY
GBIO
Financial Strength
|
Metric
|
FULC
|
CBAY
|
GBIO
|
|---|---|---|---|
Quick Ratio | 17.44 | 10.70 | 6.73 |
Current Ratio | 17.71 | 10.96 | 6.83 |
Interest Coverage | — | −5.27 | — |
Quick Ratio
FULC
CBAY
GBIO
Profitability
|
Metric
|
FULC
|
CBAY
|
GBIO
|
|---|---|---|---|
Return on Assets (Normalized) | −29.80% | −30.06% | −25.96% |
Return on Equity (Normalized) | −32.72% | −51.97% | −40.85% |
Return on Invested Capital (Normalized) | −31.22% | −30.87% | −34.11% |
Return on Assets
FULC
CBAY
GBIO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wfktzrrn | Rkm | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gfdgqqd | Xvfdxqx | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zfckfdzk | Ffkmdgj | $97.8 Bil | |
MRNA
| Moderna Inc | Hhkmdqzgf | Vfkm | $41.3 Bil | |
ARGX
| argenx SE ADR | Dylyrmwf | Djyx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Vxpdtqxn | Cysts | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hxhbsqq | Cvysl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kktwzqvd | Hfytmx | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Trxwdfdfm | Yqjtj | $12.5 Bil | |
INCY
| Incyte Corp | Mymrfvs | Mwvrjt | $11.6 Bil |